Health and Quality of Life Outcomes

As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times. Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.

​​​​​​​Invasive meningococcal disease (IMB) occurs most commonly in children. There can be challenges in estimating the long term quality of life of IMD survivors.

In this study, researchers conducted a DELPHI questionnaire to identify knowledge gaps and to seek consensus on appropriate methods and study designs when investigating the burden caused by IMD.

To read the full research article, click here.

Mark Oremus, Editor-in-Chief

Dr Mark Oremus is an Associate Professor in the School of Public Health and Health Systems at the University of Waterloo, Canada. He holds a PhD in Epidemiology and Biostatistics from McGill University.

Dr Oremus' primary research interests include aging and chronic disease, cognition, dementia, and Alzheimer’s disease. He has conducted studies on willingness-to-pay for Alzheimer’s disease medications, measuring quality-of-life in Alzheimer’s disease, and the use of outcome measurement instruments in Alzheimer’s disease drug trials. His other research interests include systematic reviews, population and public health from a life-course perspective, health policy and economics, and knowledge transfer.